Bifilac Lozenge

Bifilac Lozenge Manufacturer

Manufacturer

Manufacturer

Allianz Biosciences Pvt Ltd

Minimum Order Quantity

Minimum Order Quantity

1,25,000 Sachets

Form
Form

Lozenge

Composition
Composition

Pre & Probiotic

Key Ingredients

Each BIFILAC Lozenge contains 

  • Streptococcus faecalis T-110 JPC - 30 million 
  • Clostridium butyricum TO-A - 2 million 
  • Bacillus mesentericus TO-A - 1 million 
  • Lactic acid bacillus (Lactobacillus sporogenes) - 50 million 
Description

BIFILAC contains, Streptococcus faecalis T-110, Clostridium butyricum TO-A, Bacillus mesentericus TO-A which are patented strains, licensed from TOA Pharmaceuticals Co. ltd, Japan and Lactic acid bacillus (Lactobacillus sporogenes), which is a time tested probiotic strain. Through their symbiotic action they produce certain pathogen (Bad bacteria) inhibiting factors and in addition also produce a bifidogenic nutrient which helps in increasing the count of beneficial bacteria in the intestine. 

Get more details